Clinical trials: Essential Hypertension.
Essential Hypertension
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension
The primary objective of the study is to evaluate the safety and tolerability of single ascending doses of Vasomera (PB1046) administered subcutaneously in adult subjects with Stage 1 or Stage 2 essential hypertension.
- Trial name
- NCT01523067
- Testing
- Vasomera (PB1046), 0.9% Sodium Chloride
- Where
- 5 sites in United States
- Volunteers
- 68 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Essential Hypertension
Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
This study assessed the efficacy and safety of the valsartan/amlodipine 160/5 mg single-pill combination in patients with uncomplicated essential hypertension not adequately controlled (MSDBP ≥90 mmHg and <110 mmHg) on valsartan…
- Trial name
- NCT01001572
- Testing
- Valsartan/amlodipine 160/5 mg, Valsartan 160 mg
- Volunteers
- 932 people
- Sponsor
- Novartis
Hypertension
An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of TCV-116CCB (candesartan cilexetil and amlodipine besylate fixed-dose combination) in Chinese participants with mild to moderate hypertension who do not reach…
- Trial name
- NCT02969265
- Testing
- Amlodipine, TCV-116CCB
- Where
- 25 sites in China
- Sponsor
- Takeda
Hypertension
Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension Patients
The purpose of this study is to evaluate of efficacy and safety of HCP1904-1 and RLD2001-1 alone in patients with essential hypertension inadequately controlled on RLD2001-1 monotherapy.
- Trial name
- NCT04820907
- Testing
- HCP1904-1, RLD2001-1
- Where
- South Korea
- Volunteers
- 123 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension
Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with amlodipine in treating individuals with essential hypertension, compared to treatment with amlodipine…
- Trial name
- NCT00591266
- Testing
- Azilsartan Medoxomil and amlodipine, Amlodipine
- Where
- 50 sites in United States
- Volunteers
- 566 people
- Sponsor
- Takeda
Hypertension
A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension
The purpose of this study is to determine a safe and effective dose of ADX415 for the treatment of hypertension.
- Trial name
- NCT00779181
- Testing
- ADX415
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Addrenex Pharmaceuticals, Inc.
Hypertension
Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients With Mild to Moderate Essential Hypertension
This study will evaluate the pharmacokinetic profile, the effect of rennin inhibition and the relationship among pharmacokinetics, renin-angiotensin system (RAS) biomarkers, and blood pressure lowering effects of oral doses of…
- Trial name
- NCT00424541
- Testing
- SPP100 (aliskiren)
- Where
- Japan
- Volunteers
- 34 people
- Sponsor
- Novartis
Hypertension
Using Telmisartan Alone or Combination of Telmisartan -HCTZ in the Treatment of Mild to Moderate Essential Hypertension
The aim of this therapeutic observation is to demonstrate the efficacy and safety of telmisartan or telmisartan and HCTZ in the treatment of patients with mild-to-moderate essential hypertension under normal conditions of use…
- Trial name
- NCT00638911
- Volunteers
- 33,247 people
- Sponsor
- Boehringer Ingelheim
Hypertension, Essential
Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed
Randomized, open label, single dose, 2-way crossover study to investigate the bioequivalence of a new fixed dose combination (FDC) tablet of nifedipine GITS and candesartan with the corresponding loose combination under fed…
- Trial name
- NCT01350609
- Testing
- Nifedipine/Candesartan (BAY 98-7106), Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333)
- Where
- Germany
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Bayer
Essential Hypertension
A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension
The objective of this clinical trial is to evaluate the antihypertensive efficacy and safety of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 with essential hypertension.
- Trial name
- NCT07373613
- Testing
- BR1400-1, BR1400-2, BR1400-3
- Where
- South Korea
- Volunteers
- 330 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
MK-0954E Study in Participants With Hypertension (MK-0954E-357)
This study is being done to evaluate the efficacy, safety, and tolerability of losartan potassium 50 mg (L50) + hydrochlorothiazide 12.5 mg (H12.5) + amlodipine besylate 5 mg (A5) (MK-0954E).
- Trial name
- NCT01302691
- Testing
- losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E), Losartan potassium, Amlodipine besylate
- Volunteers
- 327 people
- Sponsor
- Merck Sharp & Dohme LLC
Essential Hypertension
Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension
This study was a non-interventional, secondary use of data, retrospective, cohort study, and the data to be extracted in this study was used as secondary use of collected patient information in the database (Japan Medical Data…
- Trial name
- NCT06604897
- Where
- United States
- Volunteers
- 1,405 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension, Primary Hypercholesterolemia
A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C
The purpose of this clinical trial is to evaluate the efficacy and safety of co-administrated BR1018B and BR1018C in patients with essential hypertension and primary hypercholesterolemia
- Trial name
- NCT06165250
- Testing
- BR1018A, BR1018A-1, BR1018B
- Where
- 2 sites in South Korea
- Volunteers
- 151 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Primary Hypertension
A National Multicentre Study to Assess the Efficacy of the Fixed Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled by Monotherapy
This study is to assess the efficacy of the fixed combination of Valsartan and Amlodipine in hypertensive patients uncontrolled by monotherapy.
- Trial name
- NCT01241487
- Testing
- valsartan/amlodipine
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Novartis
Hyperlipidemias, Hypertension
Study to Evaluate the Effect of Improving Systolic BP and LDL-C Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab
The purpose of this study is to evaluate the effectiveness of Olostar Tablet on blood pressure and lipid profiles, obtain safety-related information for subgroups that failed to participate in the clinical trials, and to evaluate…
- Trial name
- NCT05411887
- Testing
- Rosuvastatin, Olmesartan Medoxomil
- Where
- South Korea
- Volunteers
- 2,845 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Hypertension, Hypertension, Systolic
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
A prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel atrioventricular interval modulation (AVIM) algorithm downloaded into a dual-chamber Medtronic Astra/Azure…
- Conditions
- Hypertension, Hypertension, Systolic, Hypertension, Essential
- Trial name
- BACKBEAT (NCT06059638)
- Testing
- Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated, Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated
- Where
- 131 sites in United States, Australia and 13 more
- Volunteers
- 316 people
- Sponsor
- Orchestra BioMed, Inc
Essential Hypertension
Evaluation of Stendo Pulsating Suit on Microcirculation and Central Blood Pressure in Essential Hypertension Patients
The action of one Stendo pulsating suit session will be evaluated on 24 patients referred to the hypertension consultations for essential hypertension treated but not stabilized.
- Trial name
- NCT02277821
- Testing
- Stendo pulsating suit System
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Stendo
Primary Hypertension
A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components
This is a randomised, open-label; parallel group, multicentric study comparing the efficacy and safety of fixed-dose-combinations of Metoprolol XL plus Amlodipine with individual components of the combination.
- Trial name
- MARS (NCT00819104)
- Testing
- Metoprolol XL 50mg + Amlodipine 5mg, Metoprolol XL 25 mg + Amlodipine 2.5mg, Metoprolol XL 50mg
- Where
- 11 sites in India
- Volunteers
- 402 people
- Sponsor
- AstraZeneca
Lower Leg Edema, Orthostatic Hypertension
Observational Study to Evaluate the Safety and Efficacy for Levacalm Tab. Versus Valsartan/Amlodipine Combination Therapy in Essential Hypertension Patients
Levacalm Tab. was approved in Jul 2013 by MFDS in South Korea. Levacalm Tab. is combination drug of Valsartan as an angiotensin II receptor blocker and Lercanidipine as a Calcium channel blocker.
- Trial name
- NCT02415192
- Testing
- Levacalm, Valsartan/amlodipine
- Where
- South Korea
- Volunteers
- 2,001 people
- Sponsor
- LG Life Sciences
Essential Hypertension
Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
A multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients with Essential Hypertension Inadequately Controlled with AGLS
- Trial name
- NCT05503953
- Testing
- AGSAVI, AGLS
- Where
- South Korea
- Volunteers
- 318 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd